Studies have indicated that TSPYL2 can reduce gefitinib (GEF) resistance in CRC by suppressing sirt1-mediated FOXO3 deacetylation, making it a promising target for anti-tumor therapy [39]. Here, FOXO3 is linked to neoplasm.